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Article summary  
This study comprehensively characterizes a large international cohort of pediatric and adolescent 
COVID-19 patients, and almost 2 million with previous seasonal influenza across 5 countries. 
 
What’s known on this subject 
Most COVID-19 studies were targeted at adults, and data concerning children and adolescents 
are limited. Clinical manifestations of COVID-19 are generally milder in the pediatric population 
compared with adults, and hospitalization for COVID-19 affects mostly children with pre-
existing comorbidities. 
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What this study adds 
Complications including hospitalization, hypoxemia and pneumonia were more frequent in 
children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal 
symptoms could help differential diagnosis. A wide range of medications were used for the 
inpatient management of pediatric COVID-19. 
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ABSTRACT  
 
Objectives: To characterize the demographics, comorbidities, symptoms, in-hospital treatments, 
and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19, and 
to compare them in secondary analyses with patients diagnosed with previous seasonal influenza 
in 2017-2018. 
Methods: International network cohort using real-world data from European primary care 
records (France/Germany/Spain), South Korean claims and US claims and hospital databases. 
We included children/adolescents diagnosed and/or hospitalized with COVID-19 at age <18 
between January and June 2020. We described baseline demographics, comorbidities, symptoms, 
30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute 
respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and 
death.  
Results: A total of 242,158 children/adolescents diagnosed and 9,769 hospitalized with COVID-
19, and 2,084,180 diagnosed with influenza were studied. Comorbidities including 
neurodevelopmental disorders, heart disease, and cancer were more common among hospitalized 
vs diagnosed with COVID-19. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms 
were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-
19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids 
(6.8%-7.6%), famotidine (9.0%-28.1%), and antithrombotics such as aspirin (2.0%-21.4%), 
heparin (2.2%-18.1%), and enoxaparin (2.8%-14.8%). Hospitalization was observed in 0.3% to 
1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. 
Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 
than influenza. 
Conclusions: Despite negligible fatality, complications including hospitalization, hypoxemia 
and pneumonia were more frequent in children/adolescents with COVID-19 than with influenza. 
Dyspnea, anosmia and gastrointestinal symptoms could help differentiate diagnoses. A wide 
range of medications was used for the inpatient management of pediatric COVID-19. 
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INTRODUCTION 
Since January 2020, a growing number of infections by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has led to an unprecedented pressure on healthcare systems 
worldwide. COVID-19 affects all age groups, with pediatric population representing 3.7% of 
reported cases.1 
Despite children/adolescents being more susceptible to certain infectious diseases due to their 
developing immune system,2 clinical manifestations of COVID-19 are generally milder in the 
pediatric population,3,4 with better outcomes and lower mortality rates than adults.5 Nevertheless, 
there is evidence of children/adolescents with COVID-19 requiring hospitalization and intensive 
care unit (ICU)-level care. Reports from the United States (US) or China revealed that a low 
number of pediatric COVID-19 cases were hospitalized (5.7%)6 or admitted to the ICU (1.8%)7, 
respectively. A study conducted in 25 European countries, on the other hand, found that in a 
sample of 582 children/adolescents, 63% were hospitalized.8 Since the data included in this last 
study was limited to April 2020, the high admission rate reported could reflect temporal trends in 
testing availability as only the most ill children might have been tested during this period. 
To date, most clinical guidelines recommend supportive care as the mainstay of therapy in 
children,9-11 but there is little data to recommend or reject the use of specific immunomodulatory 
drugs or antivirals, particularly from clinical trials in the pediatric population.12 It also remains to 
be elucidated whether children/adolescents show a different clinical presentation.13 We 
conducted a literature review for articles published in PubMed and Medrxiv between December 
2019 and June 2020 that reported on patients with a confirmed COVID-19 diagnosis. Of the 
1320 studies that met the inclusion criteria, only 79 studies were on children/adolescents, most of 
which (63%) were local case reports or case series. This compellingly demonstrates a large 
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remaining gap in existing efforts to define the characteristics of the pediatric population in a real-
world setting at a large scale.  
In this study, we aimed to describe the demographics, comorbidities, symptoms, in-hospital 
treatments, and health outcomes of children/adolescents diagnosed or hospitalized with COVID-
19 in the US, Europe and Asia. In addition, we compared these cohorts with children/adolescents 
diagnosed with seasonal influenza in 2017-2018 as a benchmark in a secondary analysis. 
 
METHODS 
Study design, setting and data sources 
This study is part of the Characterizing Health Associated Risks, and Your Baseline Disease In 
SARS-COV-2 (CHARYBDIS) study, a large-scale multinational cohort study using routinely-
collected primary care and hospital EHRs, hospital billing data and insurance claims data from 
the US, Europe (the Netherlands, Spain, the UK, Germany and France) and Asia (South Korea 
and China).   
From the nineteen databases contributing data to CHARYBDIS, only those with data on patients 
below the age of 18 years with a clinical diagnosis of COVID-19 or a SARS-CoV-2 positive test 
between January and June 2020 were included. A cohort of children/adolescents diagnosed with 
seasonal influenza in 2017-2018 was included for comparison.  
To be included in the study, databases had to have a minimum of 140 children/adolescents). This 
cut-off was deemed necessary to estimate with sufficient precision (confidence interval width of 
±5%) the prevalence of a previous condition or 30-day risk of an outcome affecting 10% of the 
 by guest on June 2, 2021www.aappublications.org/newsDownloaded from 
Prepublication Release 
©2021 American Academy of Pediatrics 
study population. Data results for this paper were extracted from CHARYBDIS results on the 1st 
of October 2020. Figure 1 represents the selection process of the databases for this study. Eleven 
databases fulfilled the inclusion criteria: STARR-OMOP (US),14 CU-AMC HDC (US), 
HealthVerity (US), CUIMC (US), OPTUM-EHR (US), PREMIER (US), IQVIA-OpenClaims 
(US), IQVIA-LPD France (France), IQVIA-DA Germany (Germany), SIDIAP (Spain),15 HIRA 
(South Korea). Among these, five databases contributed to the hospitalized cohort: PREMIER, 
OPTUM-EHR, IQVIA-OpenClaims, CUIMC, HIRA; and three were national claims databases: 
HealthVerity, HIRA; and IQVIA-OpenClaims. A more detailed description of the included data 
sources is available in eTable 1. 
 
Study participants and follow-up 
Two non-mutually exclusive cohorts were included: 1) children/adolescents with COVID-19 
diagnosis or a SARS-CoV-2 positive test (index date was the first of the two events), 2) 
children/adolescents hospitalized (index date was hospitalization date), with COVID-19 
diagnosis or a SARS-CoV-2 positive test 21 days before or after hospitalization date. A similar 
diagnosed cohort of children/adolescents with seasonal influenza diagnosis or positive influenza 
test in 2017-2018 was also included. Study participants could contribute information to all 
cohorts (diagnosed or hospitalized with COVID-19, or diagnosed with influenza). Individuals 
diagnosed with COVID-19 could be part of the hospitalized cohort if COVID-19 was diagnosed 
during or at the time or 21 days before hospitalization. Cohort participants were followed in each 
cohort from the index date to the earliest of death, end of the observation period, or 30 days after. 
The codes used to identify COVID-19 are described in eTable 2. In order to describe history of 
comorbidities, only participants with at least 365 days of prior observation before index date 
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were included. Children below age one were excluded from the cohorts databases for which we 
requiring 365 days of prior observation.    
 
Baseline characteristics, symptoms, drug use and outcomes of interest 
Baseline information on age at index date and conditions up to 1 year before index date were 
identified. Conditions were ascertained based on the Systematized Nomenclature of Medicine – 
Clinical Terms (SNOMED CT) hierarchy, with all descendant codes included. Detailed 
definitions of each condition can be consulted in eTable 2.  
Symptoms recorded at index date included fever, cough, dyspnea, malaise or fatigue, myalgia, 
anosmia or hyposmia or dysgeusia, gastrointestinal tract symptoms, diarrhea, vomits and nausea. 
All drugs prescribed/dispensed during the 30-days follow-up after the index date were 
ascertained. Individual medications were categorized using Anatomical Therapeutic Chemical 
(ATC) groupings. For the study of medications potentially used for COVID-19, we assessed all 
medications included in at least two randomized controlled trials.16 The list was further enriched 
with suggestions from key stakeholders including regulatory agencies, key opinion leaders, and 
pharma industry. Medicines of interest were grouped into:  1) repurposed medications- those 
with alternative indications but believed to be efficacious as antivirals, 2) adjuvant therapies - 
used allegedly for the treatment or prevention of COVID-19 complications.17 All conditions and 
medications and additional time windows (a month prior and on index date) are reported in full 
and are available in an interactive website: 
https://data.ohdsi.org/Covid19CharacterizationCharybdis/. 
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The 30-day outcomes described in the diagnosed cohorts included hospitalization, death, 
pneumonia, and multi-system inflammatory syndrome in children (MIS-C, Kawasaki disease, or 
toxic shock syndrome). In the hospitalized cohorts, we additionally report sepsis, total 
cardiovascular disease events, acute respiratory disease syndrome (ARDS), cardiac arrhythmia, 
and bleeding. The definition of each outcome is provided in eTable 2. 
We used the OHDSI Cohort Diagnostics to assess the fitness of use of each comorbidity per 
database. This tool represents the codes used for the definition of each condition and the 
prevalence of these conditions by sex, age groups and calendar year for each database. Results 
from cohort diagnostics of the definitions of COVID-19, seasonal influenza, and comorbidities 





Statistical analyses  
All data were standardized to the Observational Medical Outcomes Partnership (OMOP) 
Common Data Model (CDM).18 A common analytical code for the CHARYBDIS study was 
developed for the OHDSI Methods library which was run locally in each database. Only 
aggregate results from each database were publicly shared. The CHARYBDIS protocol and 
source code can be found at https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis. 
Results were extracted from CHARYBDIS on October 1st 2020. 
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Demographics, history of comorbidities, symptoms and outcomes were summarized as 
proportions, calculated by dividing the number of people within a given category by the total 
number of people in each specific cohort. The proportion of users of each medication was 
determined for the hospitalized children/adolescents as the percentage of subjects who had >=1 
day during the time window overlapping with a drug use period for each medication or drug 
class of interest. Utilization of repurposed and adjuvant drugs up to 30 days after admission was 
described.  
The distribution of conditions a year prior to index, symptoms at index, outcomes and 
medications up to 30 days post-index date in COVID-19 diagnosed cohort were compared to the 
hospitalized COVID-19 or the diagnosed influenza cohorts. Standardized mean differences 
(SMD) were calculated when comparing the characteristics of study cohorts.  
We performed a sensitivity analysis describing characteristics of cases with no prior observation 
time in order to understand the impact of lack of prior observation time in the results.  
We used R version 3.6 (R Foundation for Statistical Computing, Vienna, Austria) for data 
visualization. All the data partners obtained Institutional Review Board (IRB) approval or 
exemption to conduct this study, as required.  
All the data partners received Institutional Review Board (IRB) approval or exemption. 
 
RESULTS 
A total of 242,158 children/adolescents diagnosed (9,769 hospitalized) with COVID-19, and 
2,084,180 diagnosed with seasonal influenza were included. Data were obtained from 5 US 
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hospital EHR databases (STARR-US [with the pediatric population representing 3.9% of all 
COVID-19 cases in this database], CU-AMC-HDC-US [2.6% of all COVID-19 cases], CUIMC-
US [4.1% of all COVID-19 cases], OPTUM-EHR-US [5.7% of all COVID-19 cases] and 
PREMIER-US [5.1% of all COVID-19 cases]), 3 European primary care records databases 
(IQVIA-LPD-France [4.0% of all COVID-19 cases], IQVIA-DA-Germany [10.0% of all 
COVID-19 cases], SIDIAP-Spain [3.7% of all COVID-19 cases]), and 2 US (HealthVerity-US 
[4.6% of all COVID-19 cases], IQVIA-OpenClaims-US [6.8% of all COVID-19 cases]) and 1 
Asian claims databases (HIRA South Korea [3.3% of all COVID-19 cases]). Up to at least 1 year 
of pre-index observation time was available only in CU-AMC-HDC-US, OPTUM-EHR-US, 
SIDIAP-Spain, and IQVIA-OpenClaims-US. Figure 1 shows a flowchart outlining the reasons 
for exclusion of additional 8 data sources available in CHARYBDIS. 
 
Demographics 
Age at diagnosis of COVID-19 varied across regions. In SIDIAP-Spain, CUIMC-US, OPTUM-
EHR-US, PREMIER-US, and STARR-US the majority of children with COVID-19 were 
diagnosed at ages 0 to 4 years (around one third), while the proportion of children from 0 to 4 
years was only 11.4% and 11.6% in IQVIA-LPD-France and CU-AMC-HDS-US, respectively. 
More consistently, most of the hospital admissions were seen in the younger groups (0-4 years), 
e.g. 57.1% of those hospitalized in CUIMC-US, and 54.2% in PREMIER-US. Male gender was 
more common in all databases except for IQVIA-LPD-France (46.6% male) and STARR-US 
(49.2%) (Table 1).  
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Comorbidities 
In patients diagnosed with COVID-19, asthma was the most common baseline comorbidity 
assessed in the year before index date, affecting 10.1% (SIDIAP-Spain) to 28.1% (IQVIA-
OpenClaims-US), followed by obesity (from 1.9% in IQVIA-LPD-France to 19.0% in OPTUM-
EHR-US). Also in the cohort of diagnosed individuals with COVID-19, we observed a high 
prevalence of congenital malformation(s) (3.2% of those diagnosed in IQVIA-OpenClaims-US 
to 10.8% in SIDIAP-Spain), neurodevelopmental disorders (1.0% of those diagnosed in IQVIA-
LPD-France to 8.2% in OPTUM-EHR-US), heart disease (1.2% in IQVIA-LPD-France to 6.9% 
in IQVIA-OpenClaims-US), type 1 diabetes mellitus (0.2% in SIDIAP-Spain to 0.4% in IQVIA-
OpenClaims-US), cancer (0.3% in SIDIAP-Spain to 3.4% in OPTUM-EHR-US), and 
chromosomal disorder(s) (0.4% in SIDIAP-Spain to 0.5% in OPTUM-EHR-US). All of these 
were more common amongst hospitalized children/adolescents with COVID-19 as compared to 
the diagnosed with COVID-19 cohort (SMD>0.1; assessed in the year before index date): 34.1% 
asthma, 18.0% obesity, 29.7% heart disease (3.0% congenital heart disease), 9.3% cancer, 3.4% 
chromosomal disorder(s), 14.0% congenital malformation(s), and 2.0% prematurity in IQVIA-
OpenClaims-US (Figure 2).  
 
Symptoms 
Figure 3 shows recorded symptoms at index date for diagnosed vs hospitalized COVID-19 
patients. The most common reported symptom in COVID-19 was fever, seen in 4.8% (SIDIAP-
Spain) to 26.4% (CUIMC-US) of diagnosed cases, and higher (up to 28.1% in CUIMC-US) 
among hospitalized cases. Second most common was cough, recorded in 4.7% (SIDIAP-Spain) 
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to 13.0% (PREMIER-US) amongst the diagnosed, and lower (e.g. 2.2% in PREMIER-US) in 
hospitalized children/adolescents. Bronchiolitis was recorded in 0.5% (SIDIAP-Spain) to 9.7% 
(STARR-US) of the diagnosed, and higher (up to 14.4% in PREMIER-US) in the hospitalized. 
Gastrointestinal tract symptoms were also common at index date, recorded in 0.5% 
(HealthVerity-US) to 12.5% (SIDIAP-Spain) in diagnosed, and up to 13.2% (IQVIA-
OpenClaims-US and PREMIER-US) among hospitalized. Anosmia was <=1% in all 
participating databases, except for COVID-19 diagnosed patients in IQVIA-OpenClaims-US 
(1.1%) and PREMIER-US (1.5%). Compared to influenza (eFigure 1), COVID-19 diagnosed 
children/adolescents had less frequently recorded symptoms by healthcare professionals in most 
databases, with the only exceptions of: dyspnea (e.g. 8.6% in COVID-19 vs 1.1% in influenza in 
STARR-US), bronchiolitis (e.g. 9-7% in COVID-19 vs 1.1% in influenza in STARR-US), 
anosmia/hyposmia/dysgeusia (e.g. 0.8% in COVID-19 vs 0.0% in influenza in IQVIA-
OpenClaims-US), and gastrointestinal tract symptoms (e.g. 10.3% in COVID-19 vs 4.5% in 
influenza in IQVIA-OpenClaims-US). 
 
In-hospital treatments 
Use of drugs during hospital admission for COVID-19 amongst children/adolescents is reported 
in Figures 4a (repurposed) and 4b (adjunctive therapies), based on data from CUIMC-US, 
OPTUM-EHR-US, PREMIER-US, and HIRA-South Korea. Repurposed treatments were not 
commonly used (<10% in all databases), with lopinavir-ritonavir used in 5.6% in HIRA-South 
Korea but not in US databases, azithromycin from 4.4% in HIRA-South Korea and OPTUM-
EHR-US to 5.8% to 5.8%% in PREMIER-US, hydroxychloroquine in 1.0% (PREMIER-US) to 
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3.6% (HIRA-South Korea), and oseltamivir only in the US, from 1.2% in OPTUM-EHR-US to 
5.6% in CUIMC-US.  
Adjunctive therapies were more common, with systemic corticosteroids used in 6.8% (HIRA-
South Korea) to 48.6% (CUIMC-US). Famotidine was the second most common adjunctive 
treatment, used in 10.0% (OPTUM-EHR-US) to 28.1% (CUIMC-US). Concomitant 
antithrombotic therapy was also common in the US but not in HIRA-South Korea (no use 
reported), including aspirin (4.8% in PREMIER-US to 21.4% in CUIMC-US), heparin (2.2% in 
PREMIER-US to 18.1% in CUIMC-US), and enoxaparin (6.0% in OPTUM-EHR-US to 11.7% 
in PREMIER-US). Antibiotics (ceftriaxone, amoxicillin, fluoroquinolones), vitamin (D and C) 




Outcomes in the 30-day period following the diagnosis of COVID-19 and hospitalization with 
COVID-19 are summarized in Table 1 and Figure 5. Hospitalization was observed in a low 
proportion (0.3% in HealthVerity-US, 1.4% in SIDIAP-Spain) in the ambulatory/claims 
databases with testing and testing results data available; in 3.5% in IQVIA-OpenClaims-US; and 
more frequent (7.6% in OPTUM-EHR-US to 33.2% in CUIMC-US) in hospital EHR databases. 
Hypoxemia and pneumonia were the most common complications. Hypoxemia was diagnosed in 
a wide range from 0.1% (HealthVerity-US) to 13.5% (STARR-US) of those diagnosed, and in 
12.9% (CUIMC-US) to 23.6% (IQVIA-OpenClaims-US) of those hospitalized with COVID-19. 
Pneumonia was diagnosed in a range from 0.1% (HealthVerity-US) to 4.5% (CUIMC-US) of 
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those diagnosed, and in 6.8% (HIRA-South Korea) to 15.6% (IQVIA-OpenClaims-US) of those 
hospitalized with COVID-19. ARDS was the most common in-hospital outcome, affecting 6.2% 
(OPTUM-EHR-US) to 16.5% (PREMIER-US) of those hospitalized with COVID-19. Sepsis 
during admission was observed in <2% (N<5; HIRA-South Korea) to 10.1% in PREMIER-US. 
Other less common outcomes are reported in Table 1. MIS-C was seen in <0.1% (N<5; SIDIAP-
Spain) to 3.1% (CUIMC-US) among diagnosed, and up to 7.6% (CUIMC-US) in hospitalized 
patients with COVID-19. 
A comparison of outcomes in those diagnosed with COVID-19 vs those diagnosed with 
influenza in previous years is depicted in eFigure 2. Hospitalization rates were higher for 
COVID-19 vs influenza-diagnosed children/adolescents (e.g. 3.5% vs 0.9% in IQVIA-
OpenClaims-US, 33.2% vs 7.4% in CUIMC-US, 30.8% vs 3.7% in STARR-US), except in 
OPTUM-EHR-US where hospitalization rates were 7.6% in COVID-19-diagnosed and 10.6% in 
influenza-diagnosed participants. Similarly, hypoxemia was more common in COVID-19-
diagnosed participants (e.g. 13.5% vs 1.7% in STARR-OMOP-US, 23.6% vs 0.3% in IQVIA-
OpenClaims-US),  and so were pneumonia (e.g. 3.1% vs 0.1% in SIDIAP-Spain, 1.8% vs 0.8% 
in IQVIA-OpenClaims-US), and -despite rare- MIS-C (e.g. 0.2% vs 0.0% in IQVIA-
OpenClaims-US, 3.1% vs <0.2% in CUIMC-US). Other outcomes had more similar risks in both 
viral infections (see eFigure 2 and eTable 3). 
In a sensitivity analysis, we replicated the analyses including participants who had no prior 
history available in their EHRs (eTable 4). Differences in symptoms or outcomes were modest, 
however it demonstrated the expected incompleteness in prevalent comorbidity. 
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DISCUSSION 
This study comprehensively reports on the largest cohort of children/adolescents with COVID-
19 to date. Overall, most cases of COVID-19 diagnosis and related hospitalizations were seen 
amongst infants and toddlers aged <4 years old, predominantly of male sex. Children/adolescents 
hospitalized with COVID-19 had a higher prevalence of comorbidities than the overall cohort of 
those diagnosed with COVID-19, including asthma, obesity, heart disease, cancer, chromosomal 
disorder(s), and congenital malformation(s). The most commonly observed symptoms were fever 
and cough, while dyspnea, bronchiolitis, anosmia and gastrointestinal tract symptoms were more 
common in children/adolescents with COVID-19 than with seasonal influenza, and may aid on 
the differentiation of COVID-19 from other viral infections. The drug utilization analysis 
suggests little use of repurposed drugs and a substantial use of adjunctive therapies among 
children/adolescents. 
Hospitalization rates were between 5- and 13-fold higher amongst those children/adolescents 
diagnosed with COVID-19 vs. those with seasonal influenza in previous years. Fortunately, 30-
day fatality following a COVID-19 diagnosis or hospitalization was low. Respiratory 
complications were over-represented among children/adolescents diagnosed with COVID-19 
compared with seasonal influenza.  
The proportion of children/adolescents under 18 years of age from all observed COVID-19 cases 
in each database varied from 2.6% to 10.0%. These values are higher than what has been 
previously reported in other studies from China (2%),19 Spain (2%),20 the US (1.7%),6 or the UK 
(0.9%),21 but in line with the WHO dashboard which reported that children (>14 years) 
accounted for 3.7% of all COVID-19 cases,1 or the Australian Health Protection Agency which 
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has reported that children/adolescents (<19 year) accounted for 4% of confirmed COVID-19 
cases in Australia.22  
Asthma and obesity were the most common baseline comorbidities in children/adolescents with 
COVID-19; this is in keeping with disease prevalence among a general pediatric population.23 
More strikingly, we observed a high prevalence of conditions that are relatively rare in 
children/adolescents, including congenital malformation/s, neurodevelopmental disorders, heart 
disease, type 1 diabetes mellitus, cancer, and chromosomal disorder/s. These conditions were 
more frequent amongst hospitalized children/adolescents with COVID-19 than those diagnosed 
with COVID-19. This is in line with previous studies suggesting that children with comorbidity 
history have higher risk of critical care admission.21,24 
The frequency of reported symptoms in our study is generally lower than what has been 
previously reported in the pediatric literature,8,21,24 suggesting an underestimation in the register 
of symptoms in the form of structured data in busy actual care settings. An important finding is 
that COVID-19 diagnosed children/adolescents presented with higher rates of dyspnea, anosmia, 
and gastrointestinal symptoms than children with seasonal influenza. This information is 
clinically relevant for differential diagnosis between COVID-19 and influenza among 
children/adolescents.  
We observed great heterogeneity across countries in the use of in-hospital treatments among 
children/adolescents with COVID-19, which is in line with previous studies in adults.25 Our 
analysis suggests little use of antiviral therapies overall, with about 5% of children/adolescents 
hospitalized with COVID-19 using lopinavir/ritonavir in South Korea (but none in the US); a 
variable proportion of use of oseltamivir (1% to 5%) in the US (but none in South Korea); a 4-
6% of use of azithromycin, and limited use of hydroxychloroquine, ranging from 1% to around 
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4% in both countries. These values are lower than what we previously reported in adults (e.g. use 
of hydroxychloroquine was 57.9% in the overall population vs. 1% in children/adolescents in 
PREMIER-US),25 but in line with recent European cohort studies in hospitalized 
children/adolescents with COVID-19. A study in the UK reported that 6% (38/591) of 
hospitalized children/adolescents with COVID-19 received antiviral drugs (30 received 
acyclovir, 7 received remdesivir, and 3 received chloroquine or hydroxychloroquine),21  while a 
study in 25 European countries including 582 children/adolescents found that 7% were treated 
with hydroxychloroquine, 3% with remdesivir, 1% with lopinavir–ritonavir, 1% with 
oseltamivir.8 In contrast, we observed substantial use of different adjunctive therapies; 
corticosteroids were used in 25-35% in the US but 7% in South Korea. Famotidine (2 to 20%), 
aspirin (10 to 30%) and vitamin D (2 to 15%) were used in the US but not in South Korea. 
Antibiotics were also commonly used, with ceftriaxone and amoxicillin amongst the most 
commonly prescribed. This is consistent with the previous study in in UK where antibiotics were 
given to 69% (415/601) of hospitalized children with COVID-19.21 
It is reassuring that occurrence of severe outcomes during the 30 days after diagnosis of COVID-
19 was rare in our study, which is in line with previous studies.8,20,21,24 MIS-C was relatively 
uncommon, affecting 0.5%-3.1% of all diagnosed cases, but up to 0.9%-7.6% of those 
hospitalized with COVID-19. These results are in line with previous studies from Europe and the 
US which have suggested that COVID-19 may be associated with MIS-C in children.26-28 A 
separate cohort study found recently that 11% of children with COVID-19 admitted to hospitals 
in the UK developed MIS-C.21 These findings are of special relevance given the severity of this 
condition. Overall, all outcomes were more frequent in children/adolescents with COVID-19 
diagnosis than those with a diagnosis of seasonal influenza in 2017-2018, suggesting more 
 by guest on June 2, 2021www.aappublications.org/newsDownloaded from 
Prepublication Release 
©2021 American Academy of Pediatrics 
severe disease prognosis in children with COVID-19 than influenza. Future research is needed to 
characterize and determine the long-term outcomes of children/adolescents affected with 
COVID-19.  
 
Strengths and limitations  
This study has some limitations. First, this study is descriptive in nature. The observed 
differences between groups should therefore not be interpreted as causal effects. Second, our 
results are based on secondary data from electronic records collected for administrative and 
clinical management purposes and re-used for research which may affect the completeness of 
data recorded (e.g. lack of information on degree of prematurity or mortality) and may have 
erroneous entries, leading to potential misclassification. Such incompleteness could be 
differential in some instances (e.g. hospital vs primary care settings) and risk information bias for 
the proposed comparisons. The under-reporting of symptoms observed in these data is a key 
finding of this study, and should be taken into consideration in previous and future similar 
reports from 'real-world' cohorts. This could be due to the high workload in healthcare systems 
caused by the pandemic, coding practices, or difficulty of ascertainment of symptoms among 
preverbal children. Another limitation of this study is the inability to differentiate between 
children/adolescents tested for SARS-CoV-2 due to the presentation of symptoms versus those 
tested as part of surveillance campaigns. Finally, the currently available data is restricted to the 
first six months of 2020 coinciding with the peak of the COVID-19 pandemic in the studied 
countries, and therefore, we were not able to evaluate the possible changes in treatment and 
prognosis over time.  
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This study is unique as our approach to characterizing children with an international scope 
allows for a wide range of variation in healthcare systems and policies against the COVID-19 
pandemic. This enables a more complete understanding of the implications of the pandemic for 
different countries and regions in scope of an international comparison. It also poses a layer of 
heterogeneity that needs to be considered in the interpretation of our findings, opening a window 
for new research questions that need to be addressed; particularly around the public health 
approach for controlling the pandemic spread and severity in children/adolescents and overall. 
This study represents, to our knowledge, the largest cohort study on pediatric COVID-19 to date, 
and the only study to provide a comparison with children/adolescents with seasonal influenza in 
2017-2018. Our data confirm low rates of complications in children with COVID-19, with severe 
cases clustering amongst children with previous comorbidities. Despite the large sample size 
available, MIS-C appears rare.  
 
Conclusions 
COVID-19 affects children/adolescents of all ages but severe outcomes are reassuringly 
uncommon. There is variability across healthcare systems in different regions of America, Asia 
and Europe that may explain the observed differences in the epidemiology and clinical 
management of the disease as well as observed outcomes. Despite negligible fatality, 
complications including hospitalization, hypoxemia and pneumonia are more frequent in 
children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal 
symptoms could help differential diagnosis.  
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Table 1. Demographics, comorbidities, symptoms and outcomes among diagnosed and hospitalized COVID-19 children/adolescents (<18 
years of age)* 
 
 At least 1 year of prior observation available No prior observation time available 












































 n=4494 n=695 n=189 n=176668 n=10166 n=251 n=6499 n=752 n=425 n=21148 n=1150 n=27038 n=185 n=210 n=2057 
Age (years) 
00-04 31.2 11.4 11.6 15.3 16.0 17.1 23.2 27.3 60.2 30.5 29.4 16.6 38.4 57.1 54.2 
05-09 28.7 23.2 23.8 23.5 21.0 16.3 24.8 19.4 15.5 18.5 28.2 20.5 16.8 15.2 12.1 
10-14 24.0 36.3 23.3 31.0 28.5 33.5 25.5 25.4 13.2 24.0 23.0 32.4 19.5 15.2 13.0 
15-19 16.1 29.2 41.3 30.3 34.5 33.1 26.4 27.9 11.1 26.9 19.5 30.4 25.4 12.4 20.7 
Gender 
Female 47.2 53.2 48.1 50.2 50.1 49.4 48.8 50.0 44.7 50.3 47.7 49.2 50.8 44.8 48.5 
Male 52.8 46.6 51.9 49.8 49.9 50.6 51.2 50.0 55.3 49.7 52.3 50.8 49.2 55.2 51.5 
SARS-CoV-2 
positive test 2.1 - - - 70.4 - - 48.1 37.2 - - 78.3 42.7 55.2 - 
Comorbidities** 
Autistic disorder 0.9 - - 1.0 1.2 - 2.9 2.5 - - - - - - - 
Neonatal disorder 2.3 - - 0.4 0.5 - 2.4 2.4 - - - - - - - 
Neurodevelopmental 
disorder 7.4 1.0 7.4 7.1 8.2 2.4 15.4 16.5 - - - - - - - 
Asthma 10.1 18.7 16.4 28.1 20.6 35.1 34.1 29.3 - - - - - - - 
Obesity 9.5 1.9 - 9.5 19.0 - 18.0 19.9 - - - - - - - 
Heart disease 1.9 1.2 - 6.9 6.7 3.6 29.7 15.4 - - - - - - - 
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cancer 0.3 - - 1.2 3.4 - 9.2 10.8 - - - - - - - 
Hypertension 0.3 - - 3.2 1.5 - 21.0 4.9 - - - - - - - 
Type 1 diabetes 
mellitus 0.2 - - 0.4 0.3 - 2.4 1.1 - - - - - - - 
Attention deficit 
hyperactivity disorder 2.2 - - 4.9 5.7 - 5.8 9.7 - - - - - - - 
Chromosomal 
disorder 0.4 - - 0.4 0.5 - 3.4 2.1 - - - - - - - 
Congenital 
malformation 10.8 - - 3.2 4.0 4.4 14.0 11.4 - - - - - - - 
Congenital heart 
disease 0.2 - - 0.4 0.5 - 3.0 2.4 - - - - - - - 
Prematurity of infant 1.0 - - 0.3 0.6 - 2.0 1.6 - - - - - - - 
Symptoms at index date  
Fever 4.8 10.1 7.9 8.4 7.8 10.0 10.7 14.1 26.4 21.8 4.2 6.2 17.8 28.1 17.3 
Cough 4.7 8.2 8.5 7.0 6.8 5.6 4.3 6.6 8.2 13.0 2.7 6.3 9.7 2.9 2.2 
Dyspnea 0.3 - - 1.7 1.1 9.6 7.8 5.1 4.7 4.5 - 0.7 8.6 10.0 8.1 
Malaise or fatigue - 1.9 - 1.1 0.9 - 1.2 1.1 - 1.2 - 1.0 - - 1.1 
Myalgia - - - 0.5 0.6 - 0.4 1.1 - 1.4 - 0.2 - - 0.3 
Anosmia OR 
Hyposmia OR 
Dysgeusia - - - 0.8 1.1 - - - - 1.5 - 0.5 - - - 
Gastrointestinal tract 
symptoms 12.5 4.3 - 2.6 2.9 8.0 13.2 10.2 8.2 6.5 1.3 0.5 10.3 9.0 13.2 
Diarrhea 4.0 - - 1.1 1.3 - 3.6 3.5 1.9 2.7 - 0.3 - - 4.1 
Vomiting 1.8 1.9 - 1.4 1.4 2.4 8.7 4.8 4.5 3.4 0.8 0.2 7.0 5.7 4.9 
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Nausea 1.4 1.9 - 1.1 1.1 2.0 4.5 3.6 - 2.2 0.8 0.1 - - 1.6 
Bronchiolitis 0.5 - - 0.3 0.3 - 3.9 3.7 8.9 2.1 - 0.1 9.7 11.4 14.4 
30-day outcomes following hospitalization 
Sepsis - - - - - - 9.4 3.9 - - - - - 3.3 10.1 
Acute respiratory 
distress syndrome 
(ARDS) - - - - - - 13.2 6.2 - - - - - 8.1 16.5 
Cardiac arrhythmia - - - - - - 8.2 3.1 - - - - - 9.0 5.9 
Bleeding - - - - - - 3.3 1.2 - - - - - - 4.1 
30-day outcomes 
Death - - - - - - - - - 0.0 - - - - - 
Hospitalisation 
episodes 1.4 - - 3.5 7.6 - - - 33.2 10.2 - 0.3 30.8 - - 
Pneumonia 3.1 - - 1.8 1.0 6.8 15.6 7.6 4.5 0.0 - 0.1 - 7.6 - 
Multi-system 
inflammatory 
syndrome in children 
(MIS-C) - - - 0.2 0.2 - 3.5 2.1 3.1 0.3 - 0.0 - 7.6 2.2 
Hypoxemia - - - 1.1 0.8 - 23.6 9.3 6.8 2.6 - 0.1 13.5 12.9 22.3 
*Proportions presented among diagnosed or hospitalized patients by database (column percentage), please note that hospitalized children/adolescents could also be included in the diagnosed 
cohorts; - data not available or below the minimum cell count required (5 individuals); children aged <1 year were excluded when at least 1 year of prior observation time was required. 
**Comorbidities are reported only in those databases with at least 1 year of prior observation time. 
Abbreviations: Colorado University Anschuz Medical Campus Health Data Compass (CU-AMC HDC), Columbia University Irving Medical Center (CUIMC), Data Analyzer (DA), Health 
Insurance Review & Assessment Service (HIRA), Information System for Research in Primary Care (SIDIAP),  STAnford medicine Research data Repository (STARR-OMOP), Longitudinal 
Patient Data (LPD). 
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Figure 1. Database selection process 
 
Colorado University Anschuz Medical Campus Health Data Compass (CU-AMC HDC), Columbia University 
Irving Medical Center (CUIMC), Clinical Practice Research Datalink (CPRD),  Data Analyzer (DA), Daegu 
Catholic University Medical Center (DCMC), Health Insurance Review & Assessment Service (HIRA), Integrated 
Primary Care Information (IPCI), Longitudinal Patient Data (LPD), Nanfang Hospital COVID-19 Research 
Database (NFHCRD), Information System for Research in Primary Care (SIDIAP), STAnford medicine Research 
data Repository (STARR-OMOP), Tufts Research Data Warehouse (TRDW), Department of Veterans Affairs (VA-
OMOP)  
*No prior observation time available and therefore excluded from description of comorbidities.  
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Figure 2. Prevalence of previous comorbidities among children/adolescents (<18 years of age) diagnosed (X axis) compared to 
hospitalized (Y axis) with COVID-19. Please note that hospitalized children/adolescents could also be included in the 
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Figure 3. Symptoms recorded at index date among children/adolescents (<18 years of age)      diagnosed compared to 
hospitalized with COVID-19. Please note that hospitalized children/adolescents could also be included in the diagnosed 
cohorts.  
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Figure 4. 30-day in-hospital use of treatments among children/adolescents (<18 years of age) with COVID-19  
A. Repurposed drugs  
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Figure 5. Main 30-day outcomes among children/adolescents (<18 years of age) diagnosed compared to hospitalized with 
COVID-19. Please note that hospitalized children(adolescents could also be included in the diagnosed cohorts. 
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Supplemental Material 
eTable 1. Overview of data sources contributing results. 
 





United States   The clinical data warehouse of 
NewYork-Presbyterian 
Hospital/Columbia University 
Irving Medical Center, New York, 
NY, based on its current and 
previous electronic health record 
systems, with data spanning over 
30 years and including over 6 







New York, NY 




Germany  IQVIA DA Germany is collected 
from extracts of patient 
management software used by GPs 
and specialists practicing in 
ambulatory care settings. Data 
coverage includes more than 34M 
distinct person records out of at 
total population of 80M (42.5%) in 
the country and collected from 
2,734 providers. Dates of service 







HealthVerity  United States  This HealthVerity derived data set 
contains de-identified patient 
information with an antibody 
and/or diagnostic test for COVID-
19 linked to all available Medical 
Claims and Pharmacy Data from 
select private data providers 









Service (HIRA)  
South Korea  National claim data from a single 
insurance service from South 
Korea. It contains the observational 
medical records (including both 
inpatient and outpatient) of a 
patient while they are qualified to 
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IQVIA Open 
Claims  
  A United States database of open, 
pre-adjudicated claims from 
January 2013 to May 2020. Data 
are reported at anonymized patient 
level collected from office-based 
physicians and specialists via office 
management software and 
clearinghouse switch sources for 
the purpose of reimbursement. A 
subset of medical claims data have 









(LPD) France  
France  LPD France is a computerised 
network of physicians including 
GPs who contribute to a centralised 
database of anonymised patient 
EMR. Currently, >1200 GPs from 
400 practices are contributing to the 
database covering 7.8M patients in 
France. The database covers a time 
period from 1994 through the 
present. Observation time is defined 
by the first and last consultation 
dates. Drug information is derived 
from GP prescriptions. Drugs 
obtained over the counter by the 
patient outside the prescription 






OPTUM-EHR  United States  Optum® de-identified COVID-19 
Electronic Health Record dataset 
represents Optum’s Electronic 
Health Record data a medical 
records database for patients 
receiving a COVID-19 diagnosis 
record or lab test for SARS-CoV-2. 
The medical record data includes 
clinical information, inclusive of 
prescriptions as prescribed and 
administered, lab results, vital 
signs, body measurements, 
diagnoses, procedures, and 
information derived from clinical 
Notes using Natural Language 
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United States  The Premier Healthcare Database 
contains complete clinical coding, 
hospital cost, and patient billing 
data from approximately 700 
hospitals throughout the United 
States representing 20% of 
inpatient hospital stays. Premier 
collects data from participating 
hospitals in its health care alliance. 
The Premier health care alliance 
was formed for hospitals to share 
knowledge, improve patient safety, 
and reduce risks. Participation in 
the Premier health care alliance is 
voluntary. Although the database 
excludes federally funded hospitals 
(e.g., Veterans Affairs), the 
hospitals included are nationally 
representative based on bed size, 
geographic region, location 
(urban/rural) and teaching hospital 
status. The database contains a 
date-stamped log of all billed items 
by cost-accounting department 
including medications; laboratory, 
diagnostic, and therapeutic 
services; and primary and 
secondary diagnoses for each 










Spain  The Information System for 
Research in Primary Care (SIDIAP; 
www.sidiap.org) is a primary care 
records database that covers 
approximately 7 million people, 
equivalent to an 80% of the 
population of Catalonia, North-East 
Spain. Healthcare is universal and 
tax-payer funded in the region, and 
primary care physicians are 
gatekeepers for all care and 
responsible for repeat prescriptions.  
Fundacio Institut 
Universitari per 
a la recerca a 
l'Atencio 
Primaria de Salut 
Jordi Gol i 
Gurina 
(IDIAPJGol), 
Barcelona, Spain  
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United States   STAnford medicine Research data 
Repository, a clinical data 
warehouse containing live Epic 
data from Stanford Health Care, the 
Stanford Children’s Hospital, the 
University Healthcare Alliance and 
Packard Children's Health Alliance 
clinics and other auxiliary data 
from Hospital applications such as 
radiology PACS. STARR platform 
is developed and operated by 
Stanford Medicine Research IT 
team and is made possible by 
Stanford School of Medicine 








CA USA  
U of Colorado 
Anschuz Medical 
Campus Health 
Data Compass  
(CU-AMC-HDC) 
United States  Health Data Compass (HDC) is a 
multi-institutional data warehouse. 
HDC contains inpatient and 
outpatient electronic medical data 
including patient, encounter, 
diagnosis, procedures, medications, 
laboratory results from two 
electronic medical record systems 
(UCHealth and Children's Hospital 
of Colorado), state-level all-payers 
claims data, and the Colorado death 
registry. Acknowledgement 
statement: Supported by the Health 
Data Compass Data Warehouse 
project (healthdatacompass.org).  
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eTable 2. Cohort definitions and codes. 
Name Atlas Link 
COVID-19   
Persons tested with a COVID-19 diagnosis record or a 
SARS-CoV-2 positive test with at least 365d prior 
observation 
https://atlas.ohdsi.org/#/cohortdefinition/202  
Persons hospitalized with a COVID-19 diagnosis record or a 
SARS-CoV-2 positive test with at least 365d prior 
observation 
https://atlas.ohdsi.org/#/cohortdefinition/197 
Persons tested with a COVID-19 diagnosis record or a 
SARS-CoV-2 positive test with no required prior 
observation 
http://atlas-covid19.ohdsi.org/#/cohortdefinition/970  
Persons hospitalized with a COVID-19 diagnosis record or a 
SARS-CoV-2 positive test with no required prior 
observation 
http://atlas-covid19.ohdsi.org/#/cohortdefinition/974  
Influenza   
Persons with Influenza diagnosis or positive test 2017-2018 
with at least 365d prior observation 
https://atlas.ohdsi.org/#/cohortdefinition/211  
Persons hospitalized with influenza diagnosis or positive 
test 2017-2018 with at least 365d prior observation 
https://atlas.ohdsi.org/#/cohortdefinition/212  
Persons with Influenza diagnosis or positive test 2017-2018 
with no required prior observation 
http://atlas-covid19.ohdsi.org/#/cohortdefinition/958  
Persons hospitalized with influenza diagnosis or positive 
test 2017-2018 with no required prior observation 
http://atlas-covid19.ohdsi.org/#/cohortdefinition/961  
Comorbidities    
Asthma    https://atlas.ohdsi.org/#/cohortdefinition/218    
Heart disease   https://atlas.ohdsi.org/#/cohortdefinition/231    
Hypertension   https://atlas.ohdsi.org/#/cohortdefinition/227    
Malignant neoplasm excluding non-melanoma skin cancer   https://atlas.ohdsi.org/#/cohortdefinition/222    
Obesity   https://atlas.ohdsi.org/#/cohortdefinition/224     
Autistic disorder 
https://atlas.ohdsi.org/#/concept/439780  
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Type 1 diabetes mellitus 
https://atlas.ohdsi.org/#/concept/201254  






Congenital heart disease 
https://atlas.ohdsi.org/#/concept/312723  
Prematurity of infant 
https://atlas.ohdsi.org/#/concept/36675035  
Outcomes    
During hospitalization 
Sepsis during hospitalization https://atlas.ohdsi.org/#/cohortdefinition/277 
Acute Respiratory Distress syndrome (ARDS) during 
hospitalization 
https://atlas.ohdsi.org/#/cohortdefinition/278  
Cardiac arrhythmia https://atlas.ohdsi.org/#/cohortdefinition/248  
Bleeding https://atlas.ohdsi.org/#/cohortdefinition/238  
30-day outcomes 
Death http://atlas-covid19.ohdsi.org/#/cohortdefinition/166 
Hospitalization episodes http://atlas-covid19.ohdsi.org/#/cohortdefinition/917   
Pneumonia http://atlas-covid19.ohdsi.org/#/cohortdefinition/938 
Multi-system inflammatory syndrome in children (MIS-C) http://atlas-covid19.ohdsi.org/#/cohortdefinition/940   
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eTable 3. Demographics, comorbidities, symptoms and outcomes among diagnosed 





























n=26929 n=22425 n=3339 
n=187422
8 n=131950 n=2112 n=19864 n=502 n=2831 
Age (years) 
00-04 22.0 20.8 23.7 24.4 23.7 40.2 29.3 21.7 25.3 
05-09 36.7 35.3 35.6 37.5 38.2 36.2 35.7 29.7 34.7 
10-14 29.2 27.0 27.0 26.3 26.6 17.2 23.3 23.7 27.8 
15-19 12.0 17.0 13.6 11.8 11.5 6.5 11.7 24.9 12.2 
Gender 
Female 47.5 47.8 49.6 48.5 48.3 48.2 47.4 50.6 46.2 
Male 52.5 51.9 50.4 51.5 51.7 51.8 52.6 49.4 53.8 
Comorbidities** 
Autistic disorder 0.5 0.0 0.9 1.0 0.8 - - - - 
Neonatal disorder 2.4 0.0 0.9 0.3 0.4 - - - - 
Neurodevelopmental 
disorder 6.7 0.6 3.5 6.4 6.6 - - - - 
Asthma 8.6 16.4 15.9 27.5 23.0 - - - - 
Obesity 8.3 1.5 3.4 4.2 12.8 - - - - 
Heart disease 1.8 0.4 2.3 4.5 4.1 - - - - 
Malignant neoplasm 
excluding non-
melanoma skin cancer 0.1 0.1 - 0.5 2.6 - - - - 
Hypertension 0.1 0.1 0.4 1.1 0.7 - - - - 
Type 1 diabetes 
mellitus 0.1 0.0 - 0.2 0.2 - - - - 
Attention deficit 
hyperactivity disorder 2.4 0.0 1.7 4.5 4.7 - - - - 
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Chromosomal disorder 0.1 0.0 0.4 0.3 0.3 - - - - 
Congenital 
malformation 11.2 0.4 2.5 2.7 2.9 - - - - 
Congenital heart 
disease 0.2 0.0 0.3 0.3 0.2 - - - - 
Prematurity of infant 0.6 - 0.4 0.2 0.3 - - - - 
Symptoms at index date 
Fever 1.7 15.9 42.1 27.9 37.9 51.8 9.3 31.3 40.6 
Cough 0.2 10.4 21.9 11.4 13.5 16.0 4.1 16.9 11.8 
Dyspnea 0.0 0.0 0.6 0.4 0.4 2.2 0.9 - 1.1 
Malaise or fatigue 0.0 1.0 0.9 0.7 0.9 0.5 0.4 - 1.1 
Myalgia 0.0 0.3 1.0 0.6 0.7 0.5 0.1 - 1.0 
Anosmia OR 
Hyposmia OR 
Dysgeusia - - - 0.0 - - - - - 
Gastrointestinal tract 
symptoms 9.6 3.2 5.6 3.4 3.7 6.1 2.3 5.4 4.5 
Diarrhea 0.6 0.0 1.3 0.5 0.6 0.9 - - 0.8 
Vomiting 1.1 2.0 3.9 2.8 2.9 4.9 1.9 4.4 3.4 
Nausea 1.1 2.0 3.5 1.6 1.9 0.6 2.0 3.2 1.4 
Bronchiolitis 0.2 0.2 1.0 0.5 0.3 0.8 0.0 - 1.1 
      
                                                            
                                                            
                                                            
                                                            
30-day outcomes 
Death - - - - - - - - - 
Hospitalization 
episodes - - 1.6 0.9 10.6 7.4 - 1.4 3.7 
Pneumonia 0.7 0.4 2.2 2.4 1.8 3.1 2.0 - 2.4 
Multi-system 
inflammatory syndrome 
in  children (MIS-C) - 0.0 - 0.0 0.0 - 0.0 - - 
Hypoxemia - - 1.7 0.3 0.3 1.5 - - 1.7 
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*Proportions presented among diagnosed or hospitalized patients by database (column percentage); - data not 
available or below the minimum cell count required (5 individuals); children aged <1 year were excluded when at 
least 1 year of prior observation time was required. 
**Comorbidities are reported only in those databases with at least 1 year of prior observation time. 
Abbreviations: Colorado University Anschuz Medical Campus Health Data Compass (CU-AMC HDC), Columbia 
University Irving Medical Center (CUIMC), Data Analyzer (DA), Health Insurance Review & Assessment Service 
(HIRA), Information System for Research in Primary Care (SIDIAP),  STAnford medicine Research data Repository 
(STARR-OMOP), Longitudinal Patient Data (LPD). 
 
eTable 4. Characteristics of diagnosed and hospitalized COVID-19 
children/adolescents with no prior observation time in those databases with 




























n = 5037 n = 979 n = 286 
n = 
201986 n = 13245 n = 251 n = 9142 n =1193 
Comorbidities** 
Autistic disorder 0.7 - - 0.3 0.3 - 1.3 1.5 
Neonatal disorder 1.7 - - 0.4 0.6 - 6.3 3.9 
Neurodevelopmental 
disorder 6.1 - - 1.3 1.4 - 4.4 7.4 
Asthma - - - 0.3 0.6 - 0.9 2.4 
Obesity - - - 0.1 0.4 - 0.6 1.8 




cancer - - - 0.0 0.1 - 0.4 0.9 
Hypertension - - - 0.1 0.1 - 0.7 0.8 
Type 1 diabetes 
mellitus 0.2 - - 0.2 0.1 - 1.7 0.8 
Attention deficit 
hyperactivity disorder 1.8 - - 0.7 0.9 - 1.5 4.1 
Chromosomal 
disorder 0.3 - - 0.2 0.2 - 1.8 1.7 
Congenital 
malformation 9.2 - - 0.7 1.2 - 7.7 7.6 
Congenital heart 
disease 0.2 - - 0.2 0.2 - 2.2 1.4 
Prematurity of infant 0.8 - - 0.1 0.3 - 1.9 1.9 
Symptoms at index date  
Fever 5.2 9.6 8.7 9.2 8.9 10.0 11.9 19.3 
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Cough 4.5 7.5 9.1 7.1 6.9 5.6 4.4 7.7 
Dyspnea 0.3 - 4.5 1.8 1.3 9.6 7.9 5.4 
Malaise or fatigue - 1.6 - 1.0 0.9 - 1.1 1.3 
Myalgia - - - 0.4 0.5 - 0.3 1.0 
Anosmia OR 
Hyposmia OR 
Dysgeusia - - - 0.8 0.9 - - - 
Gastrointestinal tract 
symptoms 11.8 3.7 - 2.9 3.3 8.0 12.2 11.2 
Diarrhea 3.7 - - 1.2 1.5 - 3.6 4.0 
Vomiting 1.7 1.6 - 1.5 1.6 2.4 7.9 6.2 
Nausea 1.4 1.6 - 1.0 1.1 2.0 3.5 3.4 
Bronchiolitis 1.3 - - 0.8 0.8 - 8.2 6.2 
30-day outcomes following hospitalization 
Sepsis - - - 0.4 0.5 - 8.7 6.0 
Acute respiratory 
distress syndrome 
(ARDS) - - - 0.5 0.7 - 12.3 7.6 
Cardiac arrhythmia - - - 0.3 0.3 - 7.0 3.3 
Bleeding - - - 0.1 0.2 - 2.9 2.3 
30-day outcomes 
Death - - - - 0.0 - - - 
Hospitalisation 
episodes 1.5 - 4.2 4.4 9.1 - - - 
Pneumonia 0.1 - - 0.8 0.7 6.4 17.1 7.7 
Multi-system 
inflammatory 
syndrome in children 
(MIS-C) - - - 0.2 0.3 - 2.8 2.7 
Hypoxemia - - - 1.3 1.2 - 22.2 11.1 
*Proportions presented among diagnosed or hospitalized patients by database (column percentage); - data not 
available or below the minimum cell count required (5 individuals). 
**Comorbidities are reported only in those databases with at least 1 year of prior observation time. 
Abbreviations: Colorado University Anschuz Medical Campus Health Data Compass (CU-AMC HDC), Columbia 
University Irving Medical Center (CUIMC), Data Analyzer (DA), Health Insurance Review & Assessment Service 
(HIRA), Information System for Research in Primary Care (SIDIAP),  STAnford medicine Research data Repository 
(STARR-OMOP), Longitudinal Patient Data (LPD). 
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eFigure 1. Symptoms recorded at index date among children/adolescents (<18 
years of age) diagnosed with COVID-19 compared to diagnosed with seasonal 
influenza (2017-2018) 
 
eFigure 2. Main 30-day outcomes among children/adolescents (<18 years of age) 
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